US 11,690,832 B2
Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones
Roshantha A. Chandraratna, San Juan Capistrano, CA (US); and Martin E. Sanders, Spring, TX (US)
Assigned to IO Therapeutics, Spring, TX (US)
Filed by Io Therapeutics, Inc., Spring, TX (US)
Filed on Jan. 26, 2022, as Appl. No. 17/585,349.
Application 17/585,349 is a division of application No. 17/150,646, filed on Jan. 15, 2021.
Application 17/150,646 is a division of application No. 16/083,799, granted, now 10,946,001, issued on Mar. 16, 2021, previously published as PCT/US2016/059772, filed on Oct. 31, 2016.
Claims priority of provisional application 62/306,479, filed on Mar. 10, 2016.
Prior Publication US 2022/0143000 A1, May 12, 2022
Int. Cl. A61K 31/4418 (2006.01); A61P 37/00 (2006.01); A61K 45/06 (2006.01); A61K 9/00 (2006.01)
CPC A61K 31/4418 (2013.01) [A61P 37/00 (2018.01); A61K 9/0043 (2013.01); A61K 9/0053 (2013.01); A61K 45/06 (2013.01)] 20 Claims
 
1. A method of treating an autoimmune gastrointestinal disorder, the method comprising administering to an individual in need thereof a therapeutically effective amount of a RXR agonist and a thyroid hormone, wherein the RXR agonist has the structure of Formula II

OG Complex Work Unit Chemistry
wherein R is H or lower alkyl of 1 to 6 carbons; or a pharmaceutically acceptable salt thereof;
wherein administration of the RXR agonist and the thyroid hormone treats the autoimmune gastrointestinal disorder in the individual more effectively than either the RXR agonist or the thyroid hormone alone.